Stephens initiated coverage of Pyxis Oncology (PYXS) with an Overweight rating and $13 price target The firm views the antibody-drug conjugate or ADC, space as “a highly promising technology” and notes that the company is nearing a pivotal event with the readout of their first-in-human, preliminary Phase 1 dose escalation study for a basket of solid tumors treated with lead asset PYX-201.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
